Buscar
Cardio Diagnostics Holdings Inc
CDIOAñadir a la lista de seguimiento
1.550USD
-0.050-3.13%
Cierre 07-24 16:00（ET）Cotizaciones retrasadas 15 min
4.59MCap. mercado
0.06P/E TTM
Más Datos de Cardio Diagnostics Holdings Inc Compañía
Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
Información de Cardio Diagnostics Holdings Inc
Símbolo de cotizaciónCDIO
Nombre de la empresaCardio Diagnostics Holdings Inc
Fecha de salida a bolsaNov 23, 2021
Director ejecutivoDogan (Meeshanthini V)
Número de empleados13
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 23
Dirección311 W. Superior Street
CiudadCHICAGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal60645
Teléfono18552269991
Sitio Web
Símbolo de cotizaciónCDIO
Fecha de salida a bolsaNov 23, 2021
Director ejecutivoDogan (Meeshanthini V)
Ejecutivos de Cardio Diagnostics Holdings Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Timur Dogan, Ph.D.
Mr. Timur Dogan, Ph.D.
Chief Technology Officer
Chief Technology Officer
107.26K
+96.01%
Dr. Warren Hosseinion, M.D.
Dr. Warren Hosseinion, M.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
3.87K
--
Dr. Robert Philibert, M.D., Ph.D.
Dr. Robert Philibert, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
3.25K
--
Mr. James Intrater
Mr. James Intrater
Independent Director
Independent Director
2.39K
--
Dr. Meeshanthini V. (Meesha) Dogan, Ph.D.
Dr. Meeshanthini V. (Meesha) Dogan, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Elisa Luqman, Esq., J.D.
Ms. Elisa Luqman, Esq., J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Paul F. Burton, J.D.
Mr. Paul F. Burton, J.D.
Independent Director
Independent Director
--
--
Ms. Wendy J. Betts
Ms. Wendy J. Betts
Independent Director
Independent Director
--
--
Mr. Peter K. Fung
Mr. Peter K. Fung
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Timur Dogan, Ph.D.
Mr. Timur Dogan, Ph.D.
Chief Technology Officer
Chief Technology Officer
107.26K
+96.01%
Dr. Warren Hosseinion, M.D.
Dr. Warren Hosseinion, M.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
3.87K
--
Dr. Robert Philibert, M.D., Ph.D.
Dr. Robert Philibert, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
3.25K
--
Mr. James Intrater
Mr. James Intrater
Independent Director
Independent Director
2.39K
--
Dr. Meeshanthini V. (Meesha) Dogan, Ph.D.
Dr. Meeshanthini V. (Meesha) Dogan, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Elisa Luqman, Esq., J.D.
Ms. Elisa Luqman, Esq., J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Cardio Diagnostics Holdings Inc?
Los cinco principales accionistas de Cardio Diagnostics Holdings Inc son: Mr. Timur Dogan, Ph.D.
¿Cuántas instituciones poseen acciones de Cardio Diagnostics Holdings Inc (CDIO)?
A fecha de 2026Q1, 38 instituciones poseen acciones de Cardio Diagnostics Holdings Inc, con un valor de mercado combinado de aproximadamente 138.49K, lo que representa el 4.68% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -23968.00.